Bullish Stocks: DISH Network Corp (NASDAQ:DISH), Yongye International, Inc. (NASDAQ:YONG), Five Below Inc. (NASDAQ:FIVE), Keryx Biopharmaceuticals (NASDAQ:KERX)

Dish Network Corp. (NASDAQ:DISH) Chairman Charlie Ergen recently contacted DirecTV Chief Executive Officer Mike White to discuss a merger of the two satellite television companies, according to several people with knowledge of the matter. DISH Network Corp (NASDAQ:DISH) stock performance was 6.28% in last session and finished the day at $62.09. Traded volume was 15.26 million shares in the last session and the average volume of the stock remained 2.48 million shares. The beta of the stock remained 1.05. DISH Network Corp (NASDAQ:DISH) insider ownership is 1.00%.

Yongye International, Inc. (NASDAQ:YONG) disclosed in a regulatory filing that on March 26 the consortium including Full Alliance International Limited, Yongye and Yongye International Merger Sub Limited submitted a proposal via electronic mail to the special committee of the board of directors of the company in which it offered to increase the previously offered merger consideration payable to holders of the publicly held shares in connection with the proposed merger from $6.69 per share to $7 per share. Yongye International, Inc. (NASDAQ:YONG) rose 13.33% to $6.80 yesterday on volume of 6.72 million shares. The intra-day range of the stock was $6.72 – $6.86. Yongye International, Inc. (NASDAQ:YONG) has a market capitalization of 344.66 million.

Five Below Inc. (NASDAQ:FIVE) reported its fourth quarter earnings on March 25, 2014. Five Below Inc. Five Below Inc. (NASDAQ:FIVE)’s stock on March 26, 2014 reported a higher of 11.42% to the closing price of $42.34. Its fifty two weeks range is $33.94 – $55.28. The total market capitalization recorded 2.26 billion. The overall volume in the last trading session was 6.64 million shares. In its share capital, Five Below Inc. (NASDAQ:FIVE) has 53.41 million outstanding shares.

Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) said it expected to benefit from proposed U.S. legislation that would continue a pricing system for dialysis drugs, sending its shares up the most in almost five months. On Wednesday, shares of Keryx Biopharmaceuticals (NASDAQ:KERX) advanced 17.39% to close the day at $16.54. Company return on investment (ROI) is -103.70% and its monthly performance is recorded as -1.55%. Keryx Biopharmaceuticals (NASDAQ:KERX) quarterly revenue growth is 27.43%.